CVToto2007.doc
Upcoming SlideShare
Loading in...5
×
 

CVToto2007.doc

on

  • 1,288 views

 

Statistics

Views

Total Views
1,288
Views on SlideShare
1,288
Embed Views
0

Actions

Likes
0
Downloads
6
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

CVToto2007.doc CVToto2007.doc Document Transcript

  • C.V. - Robert D. Toto, M.D. CURRICULUM VITAE NAME: ROBERT D. TOTO, M.D. ADDRESS: Department of Medicine Division of Nephrology UT Southwestern Medical Center at Dallas 5323 Harry Hines Blvd. Dallas, Texas 75390-8856 TEL: 214 648-3482 FAX: 214 648-2071 Email: robert.toto@utsouthwestern.edu DATE OF BIRTH: September 1, 1952, Waukegan, Illinois EDUCATION: Medical Education: 1973-1977 University of Illinois Abraham Lincoln School of Medicine; Chicago, Illinois; M.D. Undergraduate Education: 1970-1973 University of Wisconsin; Parkside Campus, Kenosha, WI POSTDOCTORAL TRAINING: 1982-1983 Nephrology Postdoctoral Fellowship; UT Southwestern Medical Center; Dallas, Texas. Director: Juha P. Kokko, M.D., Ph.D. 1980-1981 Nephrology Postdoctoral Fellowship; U.S. Public Health Service Hospital/University of California San Francisco, CA. Director: Henry N. Hulter, M.D. 1979-1980 Medical Resident; Baylor College of Medicine; Houston, TX. Director: Antonio Gotto, M.D. 1977-1979 Intern and Medical Resident (Internal Medicine); University of Michigan; Ann Director: William N. Kelley, M.D. CURRENT POSITION: The University of Texas Southwestern Medical Center at Dallas: Mary M. Conroy Professorship of Kidney Disease Professor of Internal Medicine Director of Patient-Oriented-Research in Nephrology Director of Clinical Nephrology 1
  • C.V. - Robert D. Toto, M.D. ACADEMIC APPOINTMENTS: 2000-Present Professor with Tenure, Department of Medicine UT Southwestern Medical Center 1999 –2000 Clinical Professor of Medicine UT Southwestern Medical Center (20% time) 1998-1999 Clinical Professor of Medicine UT Southwestern Medical Center at Dallas, Dallas, Texas 1997-1998 Professor with Tenure Department of Internal Medicine, Clinical Director of Nephrology Vanderbilt University Medical Center Nashville, TN 1995-1997 Professor with Tenure Department of Internal Medicine; University of Texas Southwestern Medical Center, Dallas, Texas 1989-1995 Associate Professor; Department of Internal Medicine; University of Texas Southwestern Medical Center, Dallas, Texas 1983-1989 Assistant Professor; Department of Internal Medicine; University of Texas Southwestern Medical Center, Dallas, Texas 1985-1997 Director, Clinical Nephrology; UT Southwestern Medical Center, Dallas, Texas 1986-1987 Acting Chief Division of Nephrology; UT Southwestern Medical Center at Dallas 1987-1997 Internal Medicine Housestaff Counselor; UT Southwestern Medical Center at Dallas OTHER RELEVANT PROFESSIONAL EXPERIENCE: 1998-2000 Director, Clinical Research Institute, Dallas Nephrology Associates Private Practice in Nephrology, Dallas Nephrology Associates HOSPITAL APPOINTMENTS: 1998-Present Attending Physician, Department of Medicine, UT Southwestern Medical Center Dallas Parkland Memorial and Zale-Lipshy and University at St. Paul Hospitals, Dallas, TX 1998-1999 Chief of Nephrology, Methodist Medical Center Dallas, TX 1997-1998 Attending Physician, Department of Medicine, Vanderbilt University Nashville, TN 1983-1997 Attending Physician, Department of Medicine UT Southwestern Medical Center Dallas, Parkland Memorial and Zale-Lipshy Hospitals, Dallas, TX MEDICAL DIRECTORSHIPS: 1997-1998 Medical Director, Middle Tennessee Dialysis Clinics Nashville, TN 1986-1994 Medical Director, Chronic Dialysis Unit Parkland Memorial Hospital, Dallas, TX 1987.1997Medical Director, Acute Dialysis Unit, Parkland Memorial Hospital, Dallas, TX 2001-present Medical Director, Parkland Health and Hospitals Renal Clinic 2001-present Medical Director, Acute Dialysis Unit, Parkland Memorial Hospital, Dallas, TX 2
  • C.V. - Robert D. Toto, M.D. HONORS & AWARDS: 1977 Alpha Omega Alpha Medical Honor Society 1987 Outstanding Teacher Award, Internal Medicine Housestaff, UT Southwestern Medical Center 1992 Outstanding Teacher Award, Medical Student Class of 1995, UT Southwestern Medical Center 1993 Outstanding Teacher Award, Medical Student Class of 1996, UT Southwestern Medical Center 1994 Outstanding Teacher Award, Medical Student Class of 1997, UT Southwestern Medical Center 1995 Outstanding Teacher Award, Medical Student Class of 1998, UT Southwestern Medical Center 1995 Fellow High Blood Pressure Council of The American Heart Association 1996 Outstanding Teacher Award, Medical Student Class of 1999, UT Southwestern Medical Center 1997 Outstanding Teacher Award, Medical Student Class 2000, UT Southwestern Medical Center5 2005 Mary M. Conroy Professorship in Kidney Disease 2007 Member, University of Texas Southwestern Academy of Teachers (SWAT) LICENSURE: Texas: January, 1980 # F5779 Tennessee: April, 1997 # 21857 BOARD CERTIFICATION: September, 1980 American Board of Internal Medicine November, 1982 American Board of Internal Medicine Subspecialty, Nephrology November, 1987 American Board of Internal Medicine Subspecialty, Critical Care Medicine November, 1997 American Board of Internal Medicine Subspecialty, Critical Care Medicine Re- certification MAJOR COMMITTEE ASSIGNMENTS: 2007 Career Development Committee Clinical and Translational Research, Department of Clinical Science UT Southwestern 2004-present Heme-Onc Chief Search Committee UT Southwestern at Dallas 2001-2003 Medical School Curriculum Committee at UT Southwestern at Dallas 2001-2000 Medical School Promotions Committee at UT Southwestern at Dallas 1990-1997 General Clinical Research Center Executive Committee, UT Southwestern 2000-present Medical Center at Dallas 1990-1997 Admissions Committee, UT Southwestern Medical School 1992.1997 Special Care Units Committee, Zale-Lipshy University Medical Center 1992-1997 Committee to Evaluate Clinical Competence, Department of Medicine, UT Southwestern Medical Center 1989.1997 Chiefs of Service Committee, Parkland Memorial Hospital 1997 President-Elect of the Medical Staff, Parkland Hospital 1990-1997 Credentials Committee Zale-Lipshy University Medical Center Hospital 1994-1995 Physician Survey Committee, Parkland Memorial Hospital 3
  • C.V. - Robert D. Toto, M.D. 1994-1997 Long-term Planning Committee, Outpatient Clinic, Parkland Memorial Hospital 1991 Search Committee for Vice President for Clinical Affairs UT Southwestern Medical Center at Dallas 4
  • C.V. - Robert D. Toto, M.D. EDITORIAL BOARDS AND GRANT REVIEW COMMITTEES: 2007 Chairman, Special Emphasis Panel on Chronic Kidney Disease NIH/NIDDK 2005 Chairman, Special Emphasis Panel on Chronic Kidney Disease NIH/NIDDK 2004 Special Emphasis Panel on Diseases of the Kidney NIH/NIDDK 2001-2005 Journal of American Society of Nephrology 1994-1998 Kidney International 1996-2001 American Journal of Kidney Diseases 1999-Present Section Editor, Current Opinion in Nephrology and Hypertension 1997-2005 Section Editor, Nephrology, Dialysis and Transplantation 1998-Present American Journal of Nephrology 1994, 1996, 1999, 2002 Reviewer, Special Study Sections, NIH-NIDDK/KHUD 1991-1996 Texas American Heart Association Grant-in-Aid Review Committee 1990, 1993 Ad Hoc Reviewer VA Merit Review Study Section MANUSCRIPT REVIEWER FOR OTHER SCIENTIFIC JOURNALS: American Journal of Nephrology American Journal of Physiology: Renal, Fluid and Electrolyte Annals of Internal Medicine Circulation Diabetes Diabetes Care Journal of the American Medical Association Journal of the American Society of Nephrology Journal of Diabetic Complications Hypertension Kidney International Metabolism New England Journal of Medicine MEMBERSHIPS IN PROFESSIONAL SOCIETIES: American Society of Nephrology American Federation for Clinical Research American Association for Advancement of Science American Heart Association, Kidney Council American Heart Association, High Blood Pressure Council International Society of Nephrology American Physiological Society Renal Physicians Association American Society of Hypertension Association of Clinical Research Training Program (K30) Directors National Kidney Foundation 5
  • C.V. - Robert D. Toto, M.D. MAJOR COMMITTEE ASSIGNMENTS AND OTHER EXPERIENCE IN PROFESSIONAL SOCIETIES: American Society of Nephrology Invited Speaker National Meeting San Francisco, CA, 2007 Highlights from ASN meeting 2006, Houston, Texas Highlights from ASN meeting 2006, Toronto, CA Highlights from ASN meeting 2005, Los Angeles, CA Invited Speaker National Meeting, San Diego, 2006 Invited Speaker National Meeting 2005 Chronic Kidney Disease Committee 2005 Postgraduate Education Committee 2004-present Public Policy Committee 2004 Invited Speaker Clinical Nephrology Course on Ischemic Nephropathy San Diego, CA 2003 Invited speaker ASN Postgraduate Course on Cardiovascular Disease in Patients with Chronic Kidney Disease, San Diego, CA 2003. Invited speaker ASN Postgraduate Course on Cardiovascular Disease in Patients with Chronic Kidney Disease, Philadelphia PA 2002. Editorial Board, Journal of American Society of Nephrology 2001-present Member Nominating Committee 2001 Clinical Science Committee 2001-2003 Abstract Reviewer, Dialysis Section, Annual Meeting San Francisco, CA 2001 Invited Speaker: Literature Review: Ischemic Nephropathy, Annual Meeting Toronto 2000 Scientific Program Committee Annual Meeting 1999, Clinical Nephrology Expert ASN "Fly-In" Program June 1999. Discussions on Capitol Hill with Texas Senators and Representatives: NIH Funding for Fiscal 2000 and beyond Lecturer, Board Review Course in Nephrology, San Francisco, CA 1999 Lecturer, Board Review Course in Nephrology, San Francisco, CA 1998 Abstract Reviewer, Acute Renal Failure: (Basic), Annual Meeting Philadelphia, PA 1998 Invited Speaker: Clinical Science Symposium on Hypertensive Renal Disease, 1997 Invited Speaker: Clinical Science Symposium "Treatment of Rapidly Progressive Glomerulonephritis", San Diego, CA 1995 Invited Speaker: Chairperson Short Course in Nephrology "Fluid and Acid-Base Disorders in the ICU". San Diego, CA 1995 Scientific Program Committee Annual Meeting 1994, Dialysis Expert Abstract Reviewer, Clinical Nephrology, Annual Meeting Orlando, FL 1994 Invited Speaker: "Clinicopathological Correlations in Glomerular Disease", Boston, MA. 1993 Abstract Reviewer, Clinical Nephrology, Annual meeting Boston, MA 1993 Invited Speaker: Mini-lecture: "Renal Insufficiency Due to ACE Inhibitors" Baltimore MD 1992 Abstract Reviewer, Acid-Base Disorders, Annual Meeting Washington, DC 1991 National Kidney Foundation Invited Speaker National Meeting, Orlando, FL, 2007 Program Committtee National Meeting 2007 Invited Speaker, National Meeting, Chicago, IL 2006 Invited Speaker National Meeting, Washington DC, 2005 Invited Speaker National Meeting, Chicago, IL 2004 Chairman, Scientific Advisory Board National Kidney Foundation of North Texas, 2003-present Member, Board of National Kidney Foundation of North Texas 2003-present 6
  • C.V. - Robert D. Toto, M.D. Member Scientific Advisory Committee National Kidney Foundation 2003- present Member, Committee on Proteinuria in Renal Disease (PARADE) March 1998 Invited Speaker: National Kidney Foundation Annual Clinical Nephrology Meeting Chicago, IL, “Who Should Not Receive An ACEI or ARB With Chronic Renal Disease” “Clinical Trials Update: Primary results of the AASK Trial”, Chicago, IL 2002 Invited Speaker: National Kidney Foundation Annual Meeting Clinical Science Symposium "When to Initiate Dialysis and How Much Is Enough", New Orleans, LA 1996 Invited Speaker: National Kidney Foundation of Texas Symposium on Renal Diseases "Resistant Forms of Hypertension", Lubbock, TX 1996 Invited Speaker: National Kidney Foundation of Texas "Role of Lipids in Progressive Renal Disease", Houston, TX 1995 Invited Speaker: National Kidney Foundation, Orlando, FL "Treatment of Dyslipidemia in Diabetic Nephropathy" 1994 Invited Speaker: National Kidney Foundation of Texas "Nutrition in patients with End-Stage Renal Disease" Dallas, TX 1994 Chairman, Clinicopathological Conference National Kidney Foundation Spring Clinical Meeting April 1997 International Society of Nephrology Clinical Nephrology and Dialysis Subcommittee, Buenos Aires, Argentina 1999, Chair Invited Speaker: International Society of Nephrology Meeting Madrid, Spain Symposium on New Clinical Trials in Nephrology "Results from the AASK Pilot Study" 1995 Chairman, Continuing Medical Education Course (English version) Scientific Program Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999, 1997-1999 Chairman, Dialysis Section Scientific Program Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999, 1997-1999 European Dialysis and Transplantation, Barcelona Spain, 2007 VISITING PROFESSOR ACTIVITIES: University of California at San Francisco, San Francisco, CA Renal Division, October 1990 University of Alabama, Birmingham, AL Renal Division, October 1991 University of Oklahoma, Oklahoma City, OK Renal Division, July 1992 University of Texas at Houston, Houston, TX Renal Division, December 1992 Ohio State University, Dept. of Medicine and Renal Division, Columbus, OH, March 1993 Vanderbilt University, Dept. of Medicine and Renal Division, Nashville, TN, December 1993 Brook Army Medical Center, San Antonio, TX, February 1994 University of Colorado Health Science Center Division of Nephrology, April 1995 University Medical and Dental School of New Jersey Medical Center-Robert Wood Johnson Department of Medicine and Division of Nephrology, December 1995 University of Florida at Gainesville, Nephrology and Internal Medicine, January 1996 University of Texas at San Antonio, Division of Nephrology, April 1996 Duke University Medical Center, February 19-20th 1998 University of Alabama Medical Center at Birmingham, June 4-6th, 1998 University of Indiana at Indianapolis, September 29-Oct 1, 1998 Wayne State University, Detroit MI, June 1-2, 1999 Duke University, Division of Nephrology, February 2002 University of California Irvine, Nephrology Division, June 2003 University of Michigan Medical School, Nephrology Division, December 2003 7
  • C.V. - Robert D. Toto, M.D. Yale University Medical Center Nephrology Division, December 2003 University of Colorado Denver, Colorado Nephrology Division, March 2004 University of Washington Seattle, Washington Nephrology Division, September 2004 Massachusetts General Hospital Medical Grand Rounds, September 2004 Emory University Atlanta Georgia Renal Grand Rounds, October 2004 University of Oregon Renal Grand Rounds, Portland, OR February 2005 University of California San Francisco Renal Grand Rounds May 2005 Stanford University Medical Center Renal Grand Rounds May 2005 Massachusetts General Hospital Harvard University Medical Grand Rounds January 2006 Johns Hopkins University Renal Grand Rounds November 2006 Brigham and Women’s Hospital Harvard University Renal Grand Rounds January 2007 Loma Linda University, Los Angeles, CA Medical Grand Rounds March 2007 University of Texas Health Science Center-San Antonio, San Antonio, TX. September 2007 ADVISING RESPONSIBILITIES: 1993-1994Advisory Panel, UT Southwestern Medical Center Curriculum Committee Advisor, 4th Year Medical Students, Department of Internal Medicine, UT Southwestern Medical 1989-1997Center at Dallas 1986-1997Housestaff Counselor, Department of Internal Medicine, UT Southwestern Medical Center at Dallas 2000-2001 Advisor/Counselor, UT Southwestern Department of Internal Medicine Intern 2000-present Advisor Senior Medical Students UT Southwestern Medical Center REGIONAL, NATIONAL AND INTERNATIONAL CONTRIBUTIONS: Invited Presentations: 2007 European Dialysis and Transplant Assoc, Barcelona “Anemia in Chronic Kidney Disease” 2006 2004 First International Conference on Albuminuria NY, NY. “Proteinuria in African-Americans” 2004 National Kidney Foundation National Meeting Chicago, IL “Hypertensive Nephrosclerosis” 2004 American Society of Nephrology National Meeting November 2004 St. Louis “Is there a drug for preserving kidney function in Hypertension?” 2004 American Heart Association National Conference New Orleans November. “Chronobiology of Blood Pressure-How to achieve Blood Pressure Goals” 2004 Italian Society of Nephrology Ischia, Italy October, “Heart Disease in Diabetes“ 2004 UTSW Internal Medicine Update Galleria Hotel Dallas. November. “Diabetic Nephropathy 2004 Primary Care Symposium Chicago IL. June. “Special Considerations in the Management of Diabetic Hypertension” 2003 National Kidney Foundation Clinical Nephrology Meeting Dallas, TX April “Blood pressure in chronic kidney disease: How low should you go?” 2003 American Diabetes Association “Dyslipidemia in Renal Disease Treatment” New Orleans, LA June. 2003 American Heart Association Plenary Session “May we AASK is there a special medication for lowering blood pressure in chronic kidney disease” Orlando, FL. November 2002 National Kidney Foundation Annual Clinical Nephrology Meeting Chicago, IL, “Who Should Not Receive An ACEI or ARB With Chronic Renal Disease” “Clinical Trials Update: Primary results of the AASK Trial” 8
  • C.V. - Robert D. Toto, M.D. 2001 American Society of Nephrology Annual Meeting San Francisco CA Clinical Science Symposium Update in Clinical Trials: “ Comparison of Relevant Megatrials in Nephrology” 2001 International Society of Hypertension in Blacks Las Vegas NV “Measurement of Renal Function in African Americans: Lessons from Clinical Trials” 2001 American College of Physicians Atlanta GA “Acid-Base, Hematuria and Proteinuria” seminar 2001 Medical Grand Rounds University of Oklahoma City June 13 2001 Hypertension Board Review Course, American Society of Hypertension. Chicago, IL, March 22-23 2001 NIH sponsored conference on Research Career in Clinical Nephrology, Bethesda, MD 2000 NIH sponsored conference on Research Career in Clinical Nephrology, Bethesda, MD 2000 International Society of Hypertension Symposium on Chronic Renal Failure Chicago, IL August 20 2000 International Symposium on Angiotensin II, Tokyo, Japan, "Role of AII receptor Antagonists in Renal Disease" 1999 Southeastern Dialysis and Transplant Association, New Orleans, LA. "Prevention of Progressive Renal Disease" 1999 ESRD Network 14 Annual Meeting "Non-nutritional causes of hypoalbuminemia in renal disease" 1999 The Southwest Pediatric Nephrology Study Group and The National Kidney Foundation of Texas. "Mechanisms and specific renal diseases associated with proteinuria and the nephrotic syndrome", Medical City Dallas Hospital 1998 Geriatrics and Nephrology Retreat, Jasper Lodge Alberta, Canada. Sponsored by The Hartford Foundation 1998 University of Oklahoma Critical Care Board Review Course "Approach to the Patient with Non-Oliguric Acute Renal Failure", Oklahoma City, OK 1997 University of Oklahoma Critical Care Board Review Course "Approach to the Patient with Non-Oliguric Acute Renal Failure", Oklahoma City, OK 1996 Internationaliones Medico Institute Nephrologie IMIN, "When to Initiate Dialysis and How Much is Enough" and "Timely Issues in the Use of ACE Inhibitors in Nephrology", Huatulco, Mexico 1996 National Kidney Foundation Annual Meeting Clinical Science Symposium "When to Initiate Dialysis and How Much Is Enough", New Orleans, LA 1996 National Kidney Foundation of Texas Symposium on Renal Diseases "Resistant Forms of Hypertension", Lubbock, TX 1995 American Society of Nephrology Clinical Science Symposium "Treatment of Rapidly Progressive Glomerulonephritis", San Diego, CA 1995 National Kidney Foundation of Texas "Role of Lipids in Progressive Renal Disease", Houston, TX 1995 Baylor College of Medicine Endocrinology Grand Rounds, Houston, TX. Role of Angiotensin II receptor antagonists in Hypertension and Renal Disease 1995 Master of Ceremonies General Clinical Research Center Awards Ceremony UT Southwestern Medical Center at Dallas 1995 American Society of Nephrology Chairperson Short Course in Nephrology "Fluid and Acid- Base Disorders in the ICU". San Diego, CA 1995 International Society of Nephrology Meeting Madrid, Spain Symposium on New Clinical Trials in Nephrology "Results from the AASK Pilot Study" 1994 National Kidney Foundation, Orlando, FL "Treatment of Dyslipidemia in Diabetic Nephropathy" 9
  • C.V. - Robert D. Toto, M.D. 1994 Symposium on Clinical Research Careers "Bench-to-Bedside Collaborations" Department of Clinical Nutrition UT Southwestern Medical Center, Dallas 1994 International Society of Blood Purification. Maastrict, The Netherlands "Treatment of Dyslipidemia in Renal Failure" 1994 International Society for Hypertension in Blacks. Cleveland, OH "The Progression of Renal Disease in Hypertensive Nephrosclerosis in Blacks" 1994 National Kidney Foundation of Texas "Nutrition in patients with End-Stage Renal Disease" Dallas, TX 1993 American Society of Nephrology Boston, MA. "Clinicopathological Correlations in Glomerular Disease" 1992 American Society of Nephrology Baltimore MD. "Renal Insufficiency Due to ACE Inhibitors" 1992 Invited Speaker: International Society for Advances in Prostaglandins, Thromboxane and Leukotriene Research, Florence, Italy "Role of Synthetic PGE1 analogues in Renal Disease" PROFESSIONAL LEADERSHIP ROLES RELATED TO TEACHING AND RESEARCH: 2007 Post-graduate education committee American Society of Nephrology 2007 Chairman, organizing committee National Institutes for Diabetes, Digestive and Kidney Disease “Assessing kidney function and progression of kidney disease” 2006 Program Committee National Kidney Foundation Annual meeting 2004 Organizing Committee and Faculty Member Bethesda MD, July. NIH- sponsored “Clinical Research in Kidney and Urologic Disease” 2002-present Program Director Training Program in Patient Oriented Research UT Southwestern 2002-present Program Director Annual Symposium on Techniques of Patient Oriented Research 2002 Member, NIH Task force on Clinical Trials, NIDDK, March 7-8, 2001, Washington 2001 American Society of Nephrology Abstract Reviewer Dialysis Section 2001 Chairman, Guidelines for Renal Biopsy Committee of The National Kidney Foundation Kidney and Dialysis Outcomes Quality Initiative 2001 Chairman, NIH planning committee on Preparing for Career in Clinical Research Career in Nephrology for 2001 meeting in Washington DC 2000 Member, NIH planning committee on Preparing for Career in Clinical Research Career in Nephrology September 9-10, 2000 Bethesda MD 1999-2000 Chairman, Physicians Advisory Board Spectra Renal Research 1999 Lecturer, American Society of Nephrology Board Review Course in Nephrology September 1998 San Francisco, CA 1998 Lecturer, ASN Board Review Course in Nephrology September 1998 San Francisco, CA 1998 Abstract Reviewer on Acute Renal Failure (Basic Science), American Society of Nephrology, Annual Meeting in Philadelphia, PA 1999 Chairman, Clinicopathological Conference National Kidney Foundation Spring Clinical Meeting April 1997 1997-1999 Chairman, Continuing Medical Education Course (English version) Scientific Program Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999 1997-1999 Chairman, Dialysis Section Scientific Program Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999 1996-1998 Member, Writing Committee for Medical Self-Knowledge Assessment Program, Subspecialty in Nephrology American College of Physicians 10
  • C.V. - Robert D. Toto, M.D. 1994 Abstract Reviewer, Clinical Nephrology, American Society of Nephrology, Annual Meeting in Orlando, FL 1993 Abstract Reviewer, Clinical Nephrology American Society of Nephrology Annual meeting in Boston, MA 1993-1995 Coordinator UT Southwestern Internal Medicine Board Review Course Renal Section, Dallas, Texas 1990 Abstract Reviewer, American Society of Nephrology Annual Meeting, Washington, DC 2000 NIH sponsored "Preparing for a Research Career in Clinical Nephrology" MAJOR RESEARCH INTERESTS: Mechanisms, Risk Factors and Treatment of Progressive Forms of Chronic Renal Diseases Diabetic Nephropathy: Pathogenesis, Progression and Prevention Hypertensive Nephrosclerosis Mechanism, Diagnosis and Clinical Management Dialysis Adequacy and Outcome in patients with End-Stage Renal Disease Pathophysiology, Metabolism and Clinical Consequences of abnormal plasma lipoproteins in Chronic Renal Failure Cost-Effectiveness of Renal Health Care Delivery Outcomes Research in Nephrology Epidemiology and Renal and Cardiovascular Disease GRANT SUPPORT: Active National Institutes of Health Title of Project: African-American Study of Kidney Disease and Hypertension (AASK) – Cohort Study, July 1, 2002 – Dec 31, 2007 Total Award $2,195,000 Role on Project: Principal Investigator Title of Project: UT Southwestern O'Brien Kidney Research Core Center (PI Igarashi) July 1, 2007-12 Total Award $5,880,000 Roles on Project: Co-Director Administrative Core, Director, Clinical and Translational Core Title of Project: Mentoring Program for Clinical Researchers in Nephrology May 2006 – April 2011 Total award $ 645,056 Role on Project: Principal Investigator Title of Project: Improving Outcomes in Diabetic Nephropathy October 1, 2002-June 30, 2008 Total Award: $2,000,000 Role on Project: Principal Investigator Title of Project: Curriculum in Clinical Research Award 11
  • C.V. - Robert D. Toto, M.D. July 2005-June 2010 Total Award: $1,500,000 Role on Project: Principal Investigator Title of Project: Cardiovascular Outcomes in Renal Artery Lesions (CORAL) April 2004-March 2009 Total Award: $75,000 Role on Project: Co-Investigator Title: Clinical and Translational Core O’Brien Center for Kidney Disease (PI Igarashi) July 2007-June 2012 Total Award $430,000 Role on Project: Co-Investigator Past: NIH Grantor: NIH 1 UO1 DK 453386-01 Title of Project: African-American Study of Kidney Disease and Hypertension, Pilot Study July 1992- June 1994 Total Award: $343,087 Role: Principal Investigator Grantor: NIH 1 U01 DK453386-01 Title of Project: African-American Study of Kidney Disease and Hypertension (AASK) - Full scale trial, July 1, 1994 - June 30, 2001. Total Award $3,604,267 Role: Principal Investigator Grantor: NIH R-23 DK 155362-03 Title of Project: Role of cytochrome P450 Metabolites of Arachidonic Acid in renal function Total Amount of Award and Dates: 1985-1988, $105, 000 Role: Principal Investigator Non-Federal Grantor: Bayer Pharmaceuticals Title of Project: Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival May 2000-April 2002 Total Award: $234,000 Role on Project: Principal Investigator Grantor: Bristol Myers Squibb Title of Project: The Effect of Irbesartan on Progression of Renal Disease in Type II Diabetics with Nephropathy October 1995-96 Total Award $48,000 Role: Principal Investigator 12
  • C.V. - Robert D. Toto, M.D. Grantor: Merck, Sharp and Dohme Title of Project: The efficacy and safety of Losartan/Hydrochlorothiazide in patients with chronic renal insufficiency March 1994 - December 1995 Total award $60,000 Role: Principal Investigator Grantor: Scios-Nova Title of Project: A double-blind randomized, placebo-controlled, Phase II/III, Multicenter Clinical trial to evaluate the safety and efficacy of intravenous auriculin hANP in the treatment of acute tubular necrosis July 1994 - June 1995. Total award $86,087 Role: Principal Investigator Grantor: G.D. Searle Co. Title of Project: Effect of Enisoprost on progression of renal failure in rats Total amount of award and dates: $20,000, 1988-1989 Role: Principal Investigator Grantor: G.D. Searle Co. Title of Project: Effect of Enisoprost on NSAID-induced renal insufficiency in chronic renal failure Total amount of award and dates: $98,000, 1988-1989 Role: Principal Investigator Grantor: Merck, Sharp and Dohme Title of Project: Lipoprotein Metabolism in Diabetic Nephropathy Role: Principal Investigator December 1992-December 1993 Total Amount of Award: $15,000 Grantor: Merck, Sharp and Dohme Title of Project: An Open, Multicenter Study to Evaluate the Safety, Tolerability, and Antihypertensive Efficacy of Losartan in Patients with Hypertension Associated with Renal Impairment December 1992-December 1993 Total Amount of Award and dates: $42,000 Role: Principal Investigator Grantor: Merck, Sharp and Dohme Title of Project: Control of Renal disease progression by enalapril in hypertensive nephrosclerosis July 1988-December 1991 Total Amount of Award $479,000 Role: Principal Investigator PUBLICATIONS: Original Articles: 1. Hulter HN, Toto RD, Banner EL Jr., Ilnicki LP, Sebastian A. Renal and systemic acid-base effects of chronic hypoparathyroidism in dogs. Am J Physiol 241 (Renal Fluid Electrolyte Physiol 10):F495-F501, 1981 13
  • C.V. - Robert D. Toto, M.D. 2. Hulter HN, Sebastian A, Toto RD, Banner EL Jr., Ilnicki LP. Renal and systemic acid-base effects of chronic administration of hypercalcemia-producing agents: Calcitriol, PTH, and intravenous Ca++. Kidney Int 21:445-458, 1982 3. Hulter HN, Toto RD, Ilnicki LP, Sebastian A. Chronic hyperkalemic renal tubular acidosis induced by KCl loading. Am J Physiol 244 (Renal Fluid Electrolyte Physiol 13): F255-F264, 1983 4. Hulter HN, Toto RD, Ilnicki LP, Halloran B, Sebastian A. Metabolic alkalosis in models of primary and secondary hyperparathyroid states. Am J Physiol 245 (Renal Fluid Electrolyte Physiol. 14):F450-F461, 1983 5. Hulter HN, Gustafson LE, Bonner EL Jr., Toto RD, Mackie S. Thyroid replacement in thyroparathyroidectomized dogs. Miner Electrolyte Metab 10(4):228-232, 1984 6. Toto RD, Hulter HN, Sebastian A. Renal tubular acidosis induced by dietary chloride. Kidney Int 25:26-32, 1984 7. Hulter HN, Toto RD, Sebastian AS, Mackie S, Cooke CR, Wilson TE. Effect of extracellular fluid volume depletion on renal regulation of acid-base and potassium equilibrium during prolonged mineral acid administration. J Lab Clin Med 103(6): 854-862, 1984 8. Hulter HN, Halloran BP, Toto RD, Peterson JC. Long-term control of plasma calcitriol concentration in dog and human: Dominant role of plasma calcium concentration in experimental hyperparathyroidism. J Clin Invest 76:695-702, 1985 9. Brater DC, Anderson SA, Brown-Cartwright D, Toto RD, Chen A, Jacob GB. Effect of etodolac in patients with moderate renal impairment compared with normal subjects. Clin Pharmacol Ther 38(6):674-679, 1985 10. Baum M, Toto RD. Lack of a direct effect of atrial natriuretic factor in the rabbit proximal tubule. Am J Physiol 250:(Renal, Fluid Electrolyte Physiol 19): F66-F69, 1986 11. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DC. Effects of acute and chronic dosing of nonsteroidal anti-inflammatory drugs in patients with renal insufficiency. Kidney Int 30:760-768, 1986 12. Brater DC, Anderson SA, Brown-Cartwright D, Toto RD. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and cirrhosis. Am J Kidney Dis 8:351-355, 1986 13. Toto RD, Siddhanta A, Manna S, Pramanik B, Falck JR, Capdevila J. Arachidonic acid epoxygenase: detection of epoxyeicosatrienoic acids (EETs) in human urine. Biochim et Biophys Acta 919:132-139, 1987 14. Helderman JH, Hernandez J, Sagalowsky A, Dawidson I, Glennie J, Womble D, Toto RD, Brinker K, Hull AR. Confirmation of the utility of fine needle aspiration biopsy of the renal allograft. Kidney Int 34(3):376-381, 1988 14
  • C.V. - Robert D. Toto, M.D. 15. Hernandez JA, Glennie J, Toto RD, Sagalowsky A, Dawidson I, Helderman JH. A novel use of fine-needle aspiration biopsy: documentation of acute pyelonephritis of the transplanted kidney. Transplant Proc 20(4):632-4, 1988 16. Firth BG, Phil D, Perna R, Bellomo JF, Toto RD. Cardiorenal effects of atrial natriuretic factor administration in congestive heart failure: natriuresis and diuresis without hemodynamic alterations. Am J Med Sci 297:203-208, 1989 17. Dawidson IJA, Coorpender L, Fisher D, Helderman H, Hull A, Palmer B, Peters P, Sagalowsky A, Sandor ZF, Toto R, Reisch J. Impact of race on renal transplant outcome. Transplantation 49:63-67, 1990 18. Toto RD. Acute tubulointerstitial nephritis. Am J Med Sci 299:392-410, 1990 19. Toto RD. Role of prostaglandins in NSAID-induced renal dysfunction. Adv Prostaglandin Thromboxane Leukot Res 21B: 967-74, 1991 20. Toto RD, Mitchell HC, Milam C, Pettinger WA. Reversible renal insufficiency due to converting enzyme inhibitors in hypertensive nephrosclerosis. Annals Int Med 115:513-519, 1991 21. Palmer BF, Toto RD. Severe neurologic toxicity induced by cyclospine A in three renal transplant patients. Am J Kid Dis 18(1):116-121, 1991 22. Converse RL, Jabobson TN, Toto RD, Jost CM, Cosentino F, Tarazi F, Victor R. Sympathetic overactivity in patients with chronic renal failure. New Engl J Med 327:1912-1918, 1992 23. Arrambide K, Toto RD. In: Tumor Lysis Syndrome. Semin Nephrol 13: 273-280, 1992 24. Converse RL, Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, Fouad-Tarazi F, Victor RD. Paradoxical withdrawal of reflect vasoconstriction as a cause of hemodialysis-induced hypertension. J Clin Invest 90: 1657-1665, 1993 25. Agarwal R, Toto RD. Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers Am. J. Kid. Dis. 22:296-99, 1993 26. Ahsan N, Palmer BF, Wheeler D, Greenlee R, Toto RD. Intravenous immunoglobulin induced osmotic nephrosis. Arch Intern Med 154:1985-7, 1994 27. Toto RD. Renal insufficiency due to ACE inhibitors. Miner Metab 20:193-200, 1994 28. Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoprotein in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 47:579-586, 1995 29. Toto RD, Mitchell HC, Lee H-C, Smith RD, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48(3): 851-859, 1995 30. Bankhead M, Toto RD, Star RA. Accuracy of urea removal estimated by kinetic models Kidney Int 48(3):785-793, 1995 15
  • C.V. - Robert D. Toto, M.D. 31. Toto RD. Treatment of dyslipidemia in chronic renal failure. Blood Purif 14(1):75-82, 1996 32. Toto RD, Adams-Huet B, Fenves A, Mitchell HC, Mulcahey W, Smith RD. Effect of ramipril on blood pressure and protein excretion rate in normotensive non-diabetes with proteinuria Am J Kid Dis 28:832-840, 1996 33. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens. 4(6):505-509, 1995 34. Toto RD, Vuitch F. A non-compliant hemodialysis patient with severe secondary hyperparathyroidism. Semin Nephrol 9:424-427,1996 35. Wright JT, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 17:3S-16S, 1996 36. Toto RD, Kirk KA, Coresh J, Agodoa LY, Olutande B, Agodoa L. Evaluation of serum creatinine as an estimate of the glomerular filtration rate in African-Americans with hypertensive nephrosclerosis: Results for the African American Study of Kidney Disease and Hypertension (AASK Pilot Study). J Am Soc Nephrol 8(2): 279-287, 1997 37. Mitchell HC, Smith R, Cutler J, Sica D, O'Conner D, Toto RD. Racial differences in the renal response to blood pressure lowering during chronic angiotensin converting enzyme inhibition: A prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensives with mild to moderate renal insufficiency. Am J Kidney Dis 29(6): 897-906, 1997 38. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S. Efficacy and tolerability of losartan in Patients with chronic renal insufficiency. Hypertension 31(2):684-91,1998 39. Coresh J; Toto RD; Kirk KA; Whelton PK; Massry S; Jones C; Agodoa L; Van Lente F. Creatinine clearance as a measure of GFR in screenees for the African- American Study of Kidney Disease and Hypertension pilot study. Am J Kidney Dis 32(1):32-42, 1998 40. Smith AC, Toto RD, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 54: 889-896, 1998 41. Toto RD, Vega GL, Grundy SM. Effect of Pravastatin on the metabolism of low-density lipoprotein in nephrotic dyslipidemia. Am J Nephrol I20:12-17, 2000 42. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am. J. Kid. Dis 36(3):646-661, 2000 43. Toto RD. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 25:161(12):1492-9, 2001 16
  • C.V. - Robert D. Toto, M.D. 44. Elliott WJ, Maddy R, Toto R, Bakris G. Hypertension in patients with diabetes. Overcoming barriers to effective control. Postgrad Med 107(3):29-32, 35-6, 2000 45. Rosenthal D, Beccerra C, Toto RD, Carbone DP, Frenkel EP. Reversible renal toxicity resulting from high single-doses of the new radiosensitizer gadolinium texaphyrin. Am J Clin Onc 23(6):593-8, 2000 46. Jafar T, Schmid CH, Landa M, Giatras I, Lau J, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Levey A. Angiotensin-converting enzyme inhibitors and progression of disease. A meta-analysis of patient-level data. Ann Int Med 135(2)73-87, 2001 47. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, The Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001 48. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001 49. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER III, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285(21):2719-2728, 2001 50. Toto RD. Hypertension and kidney literature review. Clin Nephrol 58(4):253-259, 2002 51. Tuncel M, Augustyniak R, Zhang W, Toto RD, Victor RG. Sympathetic nervous system function in renal hypertension. Curr Hypertens Rep 4(3):229-236, 2002 52. Augustyniak R, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 20(1):3-9, 2002 53. Toto RD. Hypertension and the failing kidney. Curr Opin Nephrol Hypertens 10(2):165-166, 2001 54. Toto RD. Appropriate drug therapy for improving outcomes in diabetic nephropathy. Curr Diab Rep 2:545-552, 2002 55. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347(25):2010-9, 2002 17
  • C.V. - Robert D. Toto, M.D. 56. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas- Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288(19):2421-31, 2002 57. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Bibeiro AB, Shahinfar S, Simpson RL, Snapinn SM and Toto R. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63(4):1499-507, 2003 58. Mohanram A, Toto RD. Outcome studies in diabetic nephropathy. Semin Nephrol 23(3):255-71, 2003 59. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, de Zeeuw D, Kamper AL, Strangaard S, Levy AS. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 18(10)2047-53, 2003 60. Kaysen GA, Greene T, Daugirdas JT, Kimmel PL, Schulman GW, Toto RD, Levin NW, Yan G; HEMO Study Group. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 42(6):1200-11, 2003 61. Toto RD. Hypertensive nephrosclerosis in African Americans. Kidney Int 64(6):2331-41, 2003 62. Toto RD. Anemia of chronic disease: past, present, and future. Kidney Int Suppl 87:S20-3, 2003 63. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42(4):617-22, 2003 64. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139(4):244-52, 2003 65. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23(5):307-14, 2003 66. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS; for the HEMO Study Group. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65(6):2380-9, 2004 67. Abosaif NY, Arije A, Atray NK, Baade KJ, Barboza JA, Basci A, Becker GJ, Bellorin-Font E, Beto JA, Bhaskaran M, Bilous R, Botev RC, Burchell K, Burden R, Burrowes JD, Byrd LH, Campese VM, Carroll LE, Charra B, Conley L, Depner TA, Dwyer J, Dy G, Fimian D, Finkelstein 18
  • C.V. - Robert D. Toto, M.D. FO, Gagne S, Gargan C, Gates WH, Golper TA, Gonyea JE, Greene JH, Haley WE, Hartman J, Hogg RJ, Hogue ML, Hull AR, Jha V, Johnson RJ, Kadiroglu AK, Krause ES, Kurokawa K, Langman CB, Lerma E, Leunissen KM, Levin NW, Linus SJ, Locatelli F, London G, Makhuli M, Michael MA, Moist LM, Molitch ME, Mooty J, Morad Z, Mouratoff J, Nafar M, Narva AS, Nissenson AR, Obrador GT, Parekh R, Parra D, Patel TG, Payne G, Pizzarelli F, Prisant LM, Ranganna K, Reams SM, Riesland R, Ritz E, Roberts PJ, Rossert J, Saxena R, Scantlebury V, Schoolwerth AC, Segal P, Sheps SG, Sirenko Y, Spry LA, Stair GA, Steinman TI, Thavarajah S, Thorpe R, Toto RD, Tutor R, Tuttle KR, Van Wyck DB, Vanholder R, Vassalotti J, Walker R, Wang H, Wauters JP, Wenger N, Whicombe H, Will EJ, Williams ME. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 1):S1-290, 2004 68. Depner T, Daugirdas J, Greene T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek J, Levin N, Macon E, Milford E, Owen W, Star R, Toto R, Eknoyan G; Hemodialysis Study Group. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int 65(4):1386-94, 2004 69. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 16:507-513, 2004 70. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr, AASK Study Group. A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol 15(12):3175-83, 2004 71. Toto RD. Lessons learned from recent clinical trials in hypertensive diabetics: what's good for the kidney is good for the heart and brain. Am J Hypertens 17(11 Pt 2):7S-10S, 2004 72. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens (Greenwich) 6(11 Suppl 3):2-7, 2004 73. Toto RD. Proteinuria and hypertensive nephrosclerosis in African Americans. Kidney Int Suppl 92:S102-4, 2004 74. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24(4):453-60, 2004 75. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66(3):1131-8, 2004 76. Toto RD, Rinner S, Ram CV. ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents? Postgrad Med 116(2):11-6, 19-22, 48, 2004 77. Mohanram A, Zhang X, Shahnfar S, Keane W, Brenner B, Toto RD. Anemia and the risk of ESRD in Type 2 Diabetes with Nephropathy. Kidney Int 66:1131-8, 2004 78. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens 6(Suppl 3):2-7, 2004 19
  • C.V. - Robert D. Toto, M.D. 79. Bakris GL, Toto RD, McCullough PA. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens 19(2):139-44, 2005 80. Wiederkehr M, Toto R, Fenves AZ, Ram CV. Hypertension and the kidney. Semin Nephrol. 2005 Jul;25(4):236-45. Review. 81. Toto RD. Management of hypertensive chronic kidney disease: role of calcium channel blockers. J Clin Hypertens (Greenwich). 2005 Apr;7(4 Suppl 1):15-20. Review 82. Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R, Toto R, Eknoyan G; Hemodialysis Study Group. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". J Am Soc Nephrol. 2005 Nov;16(11):3371-80. Epub 2005 Sep 28. 83. Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER III, Ojo A, Sika M, Wilkening B, Toto RD. Blood pressure control, drug therapy, and kidney disease. Hypertension 46:44-50, 2005 84. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149:408-13, 2005 85. Toto RD. Treatment of hypertension in chronic kidney disease. Semin Nephrol 2005 25:435-9, 2005 86. Toto RD. Heart disease in diabetic patients. Semin Nephrol 2005 Nov;25(6):372-8. Review. 87. Toto RD. Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent? Curr Hypertens Rep 7:374-8, 2005 88. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28:2686-90, 2005 89. Reddan D, Hasselblad V, Lowrie E, Szczech L, Lindsay R, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman L, Califf R, Owen W. A trial of intradialytic blood volume monitoring in hemodialysis patients. J Am Soc Neph 2005 16:2162-9, 2005 90. Toto RD. Lessons from the African-American Study of Kidney Disease and Hypertension: an update. Curr Hypertens Rep 8:409-12, 2006 91. Toto RD. Pressure, waves, and kidney outcomes in kidney transplant donors and recipients. Hypertension 47:141-2, 2006 92. Henrich WL, Clark RL, Kelly JP, Buckalew VM, Fenves A, Finn WF, Shapiro JI, Kimmel PL, Eggers P, Agodoa LE, Porter GA, Shapiro S, Toto R, Anderson T, Cupples LA, Kaufman DW. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study. J Am Soc Nephrol 17:1472-80, 2006 20
  • C.V. - Robert D. Toto, M.D. 93. Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M, Feldman H, Gassman J, Lea J, Kopple J, Sika M, Toto R, Greene T. Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. J Am Soc Neph 17:2000-9, 2006 94. Ng YH, Meyer KB, Kusek JW, Yan G, Rocco MV, Kimmel PL, Benz RL, Beddhu S, Dwyer JT, Toto RD, Eknoyan G, Unruh ML. Hemodialysis timing, survival, and cardiovascular outcomes in the Hemodialysis (HEMO) Study. Am J Kidney Dis 47:614-24, 2006 95. Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. Epub 2006 May 17 96. Baber U, Toto RD, de Lemos JA. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J 153:471-7, 2007 97. Gilbert RE, Kim SA, Tuttle KR, Bakris GL, Toto RD, McGill JB, Haney DJ, Kelly DJ, Anderson PW. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 30:995-6, 2007 98. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J; AASK Study Group. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006 Nov;48(5):739-51. 99. Teiwes J, Toto RD. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens 20:109-17, 2007 100.Inrig JK, Oddone EZ, Hasselblad V, Gillespie B, Patel UD, Reddan D, Toto R, Himmelfarb J, Winchester,JF, Stivelman J, Lindsay RM, Szczech LA. Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 71:454-61, 2007. 101.Beddhu S, Cheung AK, Larive B, Greene T, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G; Hemodialysis (HEMO) Study Group. Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. J Ren Nutr. 2007 Nov;17(6):372-80. 102.Sika M, Lewis J, Douglas J, Erlinger T, Dowie D, Lipkowitz M, Lash J, Cornish-Zirker D, Peterson G, Toto R, Kusek J, Appel L, Kendrick C, Gassman J; AASK group. Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis. 2007 Jul;50(1):78-89, 89.e1. 103.George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007 Feb;49(2):e23-9. 104. 105. 21
  • C.V. - Robert D. Toto, M.D. Invited Reviews: 1. Preisig PA, Toto RD, Alpern RJ. Carbonic anhydrase inhibitors. Renal Physiol Basel 10:136-159, 1987 2. Toto RD. Converting enzyme inhibitors treatment of hypertension and the kidney. AKF Newsletter 10:(4) 41-52, 1993 3. Toto RD, Vega GL, Grundy SM. Mechanisms and treatment of dyslipidemia of renal diseases. Curr Opin Hypertens Nephrol 2: 784-790, 1993 4. Toto RD, Mitchell HC, Pettinger WA. Treatment of hypertension in non-diabetic renal disease. Curr Opin Hypertens Nephrol 3:279-285, 1994 5. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and PAH. Curr Opin Hypertens Nephrol 4:505-509, 1995 6. Toto RD. Angiotensin-II receptor blockade: an innovative treatment for cardiovascular disease Postgrad Med November 1995 7. Toto RD. Angiotensin II receptor blockers and their role in the treatment of hypertension. Curr Nephrol Hypertens 19(7):218-225, 1996 Editorials and Book Chapters: 1. Alpern RJ, Toto RD. Hypokalemic nephropathy - A clue to cystogenesis? N Engl J Med 322:398-399, 1990 2. Toto RD. Assessing the evolution of atherosclerotic renal artery stenosis. Kidney Int 53(3):794-5, 1998 3. Toto RD. "Acute tubulointerstitial nephritis" in Clinical Nephrology 2nd edition, eds: Jacobson HR, Eknoyan G and Stryker GE. Williams and Wilkins 1996 4. Toto RD. "Metabolic derangements associated with diuretic use: Insulin resistance, dyslipidemia, hyperuricemia and antiandrogenic effects" in Diuretics, eds Seldin DW and Giebisch G. Raven Press 1998 5. Toto RD. "Acute tubulointerstitial nephritis caused by diuretics" in Diuretics, eds Seldin DW and Giebisch G. 1st Edition, Raven Press 1998 6. Toto RD. "Approach to treatment of mild hypertension." in Current Therapy in Nephrology and Hypertension. Mosby 1998 7. Toto RD. "Pharmacologic therapy of mild to moderate hypertension". R.J. Glassock, Editor. (4th Edition) Mosby 1998. Chapter: Hypertension - Current Therapy In Nephrology and Hypertension, pgs. 317-322 22
  • C.V. - Robert D. Toto, M.D. 8. Toto RD. "Salt Wastage" in The Kidney: Physiology and Pathophysiology, 2nd Edition. eds Seldin DW and Giebisch G. New York, Raven Press. 1998 9. Toto RD. "Dyslipidemia in chronic renal failure" in Principles and Practice of Dialysis, ed. William N. Henrich. Williams and Wilkins 1998 10. Toto RD. "Approach to the patient with acute renal failure" in Nephrology Primer, National Kidney Foundation, 1998 11. Toto RD, Vega GL, Grundy GM. "Cholesterol management in patients with clinical renal disease". H.R. Brady & C.S. Wilcox (eds)., W.B. Saunders Company. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney, Chapter 70, pgs. 491-496, 1999 12. Toto RD. "Salt Wastage", in The Kidney: Physiology and Pathophysiology, 3rd Edition. D.W. Seldin and G. Giebisch (eds). New York, Raven Press. 2002 13. Toto RD, Grundy S, Vega GL. "Treatment of dyslipidemia in chronic renal disease" in Companion to The Kidney, eds Wilcox C. and Brady H. 2nd Ed. Williams and Wilkins. 2003. 14. Toto RD. “Lipid lowering and progression of kidney disease” in The Kidney and Hypertension George Bakris (ed). Martin Dunitz, London England 2003. 15. Toto RD. “Dyslipidemia in dialysis patients” in Principles and Practice of Dialysis William Henrich (ed). Lippincott Williams and Wilkins Philadelphia, PA 2004. 16. Toto RD. "Approach to the Patient with Renal Disease" in The Kidney, ed Brenner and Rector. Williams and Wilkins 2004. 17. Mohanram A, and Toto RD. "Measurement of Renal Function" in Kidney Disease, ed Periera B and Levey A. 2004. 18. Toto RD. "Lipid lowering and progression of kidney disease" in The Kidney and Hypertension, ed Bakris. Martin Dunitz 2004. 19. Toto RD. "Hypertension in Chronic Kidney Disease" in Secondary Hypertension, ed Mansoor. Humana 2004. 20. Mohanram A, Toto RD. “Measurement of kidney function” in Chronic Kidney Disease, Dialysis, & Transplantation: A Companion to Brenner and Rector’s The Kidney Second Edition, eds B.J.G. Pereira, M.H. Sayegh and P Blake. Elsevier, Philadelphia,PA 2005 21. Ramesh S., Toto, R.D. Approach to the Patient with Renal Disease in The Kidney, 8th edition, ed. Brenner and Rector, Williams and Wilkins 2007. 22. Toto, R.D., Vega GL, Grundy SM. Management of Dyslipidemia in Chronic Kidney Disease in The Kidney, compantion to Brenner and Rector. Eds. Wilcox and Mitch, in press 2007 Williams and Wilkins 23. Toto, RD. Renal Biopsy in Pathology of the Kidney. Eds: Zhou and Silva in press 2007 Churchill and Livingston. 23